GSEP
ADMA icon

Golden State Equity Partners’s ADMA Biologics ADMA Stock Holding History

Golden State Equity Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50
Closed -$450 – 370
2026
Q1 		$450 Buy
+50
New +$789 ﹤0.01% 1896

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Golden State Equity Partners's ADMA Position: Q2 2026 in Review

Golden State Equity Partners sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 50 shares — an estimated $450 sold.

Golden State Equity Partners first reported a position in ADMA in Q1 2026 and held it in 1 quarter. The position peaked at $450 in Q1 2026. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Golden State Equity Partners reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 50 ADMA Biologics shares in Q2 2026, an estimated $450.
  • Golden State Equity Partners first reported a position in ADMA Biologics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's ADMA Biologics position peaked at $450 in Q1 2026.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.